APSR IDI Online KlikPDPI Halaman Admin Forum Umum Facebook Page Twitter Instagram Youtube
Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic re
PDPI Malang, 12 Nov 2022 09:00:24

Fajri Gafar, Roeland E. Wasmann, Helen M. McIlleron, Rob E. Aarnoutse, H. Simon Schaaf, Ben J. Marais, Dipti Agarwal, Sampson Antwi, Nguyen D. Bang, Adrie Bekker, David J. Bell, Chishala Chabala, Louise Choo, Geraint R. Davies, Jeremy N. Day, Rajeshwar Dayal, Paolo Denti, Peter R. Donald, Ephrem Engidawork, Anthony J. Garcia-Prats, Diana Gibb, Stephen M. Graham, Anneke C. Hesseling, Scott K. Heysell, Misgana I. Idris, Sushil K. Kabra, Aarti Kinikar, Agibothu K. Hemanth Kumar, Awewura Kwara, Rakesh Lodha, Cecile Magis-Escurra, Nilza Martinez, Binu S. Mathew, Vidya Mave, Estomih Mduma, Rachel Mlotha-Mitole, Stellah G. Mpagama, Aparna Mukherjee, Heda M. Nataprawira, Charles A. Peloquin, Thomas Pouplin, Geetha Ramachandran, Jaya Ranjalkar, Vandana Roy, Rovina Ruslami, Ira Shah, Yatish Singh, Marieke G. G. Sturkenboom, Elin M. Svensson, Soumya Swaminathan, Urmila Thatte, Stephanie Thee, Tania A. Thomas, Tjokosela Tikiso, Daan J. Touw, Anna Turkova, Thirumurthy Velpandian, Lilly M. Verhagen, Jana L. Winckler, Hongmei Yang, Vycke Yunivita, Katja Taxis, Jasper Stevens, Jan-Willem C. Alffenaar, for the Global Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in Pharmacokinetics of Anti-TB Drugs
European Respiratory Journal 2022; DOI: 10.1183/13993003.01596-2022


Background Suboptimal exposure to antituberculosis drugs has been associated with unfavourable treatment outcomes. We aimed to investigate estimates and determinants of first-line antituberculosis drug pharmacokinetics in children and adolescents at a global level.

Methods We systematically searched MEDLINE, Embase, and Web of Science (1990–2021) for pharmacokinetic studies of first-line antituberculosis drugs in children and adolescents. Individual patient data were obtained from authors of eligible studies. Summary estimates of total/extrapolated area under the plasma concentration-time curve (AUC0–24) and peak plasma concentration (Cmax) were assessed with random-effects models, normalised with current WHO-recommended paediatric doses. Determinants of AUC0–24 and Cmax were assessed with linear mixed-effects models.

Results Of 55 eligible studies, individual patient data were available for 39 (71%), including 1628 participants from 12 countries. Geometric means (95% CIs) of steady-state AUC0–24 were summarised for isoniazid (18.7 [15.5−22.6] h·mg·L−1), rifampicin (34.4 [29.4−40.3] h·mg·L−1), pyrazinamide (375.0 [339.9−413.7] h·mg·L−1), and ethambutol (8.0 [6.4−10.0] h·mg·L−1). Our multivariate models indicated that younger age (especially <2 years) and HIV-positive status were associated with lower AUC0–24 for all antituberculosis drugs, while severe malnutrition was associated with lower AUC0–24 for isoniazid and pyrazinamide. N-acetyltransferase 2 rapid acetylators had lower isoniazid AUC0–24 and slow acetylators had higher isoniazid AUC0–24 than intermediate acetylators. Determinants of Cmax were generally similar to those for AUC0–24.

Conclusion This study provides the most comprehensive estimates of plasma exposures to first-line antituberculosis drugs in children and adolescents. Key determinants of drug exposures were identified. These may be relevant for population-specific dose adjustment or individualised therapeutic drug monitoring.

Fakta Varian Omicron
Uploaded on Dec 13, 2021
Bahaya Debu Abu Vulkanik pada Kesehatan
Uploaded on Dec 10, 2021
Juara I - PDPI Cab Surakarta
Uploaded on March 27, 2022
Juara II - PDPI Cab Yogyakarta
Uploaded on March 27, 2022
Juara III - PDPI Cab Malang
Uploaded on March 27, 2022